Thomas J Herzog

Author PubWeight™ 163.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA 2013 4.67
2 Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010 3.33
3 Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol 2012 2.59
4 Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol 2005 2.26
5 Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013 2.24
6 Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007 2.20
7 Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol 2011 2.19
8 Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 2009 2.15
9 Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol 2004 2.08
10 Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 2013 2.05
11 Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012 1.98
12 Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol 2010 1.98
13 Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol 2011 1.86
14 Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003 1.83
15 Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol 2009 1.75
16 Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol 2013 1.72
17 Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol 2002 1.72
18 Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer 2005 1.68
19 Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 2011 1.66
20 Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care 2002 1.65
21 Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol 2012 1.58
22 Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004 1.57
23 Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. Obstet Gynecol 2010 1.56
24 The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. Obstet Gynecol 2010 1.56
25 Scientific evidence underlying the American College of Obstetricians and Gynecologists' practice bulletins. Obstet Gynecol 2011 1.55
26 Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010. Obstet Gynecol 2012 1.55
27 A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol 2013 1.54
28 Contemporary management of endometrial cancer. Lancet 2012 1.51
29 Variation in ovarian conservation in women undergoing hysterectomy for benign indications. Obstet Gynecol 2013 1.46
30 Postpartum sterilization: small incision, big complication. Obstet Gynecol 2008 1.40
31 Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys 2005 1.39
32 Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 2003 1.36
33 SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010 1.27
34 Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009 1.24
35 Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery. Obstet Gynecol 2011 1.21
36 Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005 1.20
37 The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 2008 1.17
38 Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 2011 1.16
39 Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004 1.15
40 Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol 2011 1.14
41 Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol 2012 1.14
42 Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 2013 1.13
43 MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer 2002 1.12
44 Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 2008 1.12
45 The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008 1.12
46 Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 2003 1.10
47 Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 2012 1.09
48 Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer 2014 1.08
49 The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. Am J Obstet Gynecol 2007 1.05
50 Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009 1.04
51 Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol 2013 1.03
52 Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery. Obstet Gynecol 2013 1.03
53 Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003 1.03
54 Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol 2012 1.02
55 CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 2007 1.01
56 Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. Am J Obstet Gynecol 2012 1.01
57 A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007 1.00
58 The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2009 1.00
59 Therapeutic role of lymphadenectomy for cervical cancer. Cancer 2010 1.00
60 Sarcoma of the cervix: natural history and outcomes. Gynecol Oncol 2010 1.00
61 Morbidity and mortality of peripartum hysterectomy. Obstet Gynecol 2010 1.00
62 Patterns of care and treatment outcomes for elderly women with cervical cancer. Cancer 2011 1.00
63 ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? Gynecol Oncol 2009 0.98
64 Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 2005 0.98
65 The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. Am J Obstet Gynecol 2012 0.97
66 The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol 2002 0.96
67 Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002 0.96
68 Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol 2011 0.96
69 Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 2012 0.95
70 Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 2010 0.95
71 Natural history of established low grade cervical intraepithelial (CIN 1) lesions. Anticancer Res 2008 0.94
72 Adherence to evidence-based guidelines for preoperative testing in women undergoing gynecologic surgery. Obstet Gynecol 2010 0.94
73 Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol 2005 0.94
74 The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004 0.94
75 Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer. Gynecol Oncol 2013 0.94
76 Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2004 0.94
77 Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. Gynecol Oncol 2011 0.93
78 The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. Am J Obstet Gynecol 2011 0.93
79 Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 2008 0.93
80 Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery. Ann Surg 2011 0.93
81 Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy. Obstet Gynecol 2011 0.92
82 Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. Gynecol Oncol 2012 0.92
83 Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2008 0.92
84 A review of the current evidence for maintenance therapy in ovarian cancer. Gynecol Oncol 2009 0.92
85 Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol 2010 0.91
86 Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 2004 0.91
87 Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis. Oncologist 2014 0.91
88 Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 2002 0.90
89 Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther 2008 0.90
90 Age considerations when vaccinating against HPV. Gynecol Oncol 2008 0.90
91 Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells. J Gynecol Oncol 2010 0.90
92 FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003 0.89
93 Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010 0.89
94 Targeted therapies in epithelial ovarian cancer. J Oncol 2010 0.89
95 The impact of cervical cancer on quality of life: a personal account. Gynecol Oncol 2008 0.89
96 Patterns of use of hemostatic agents in patients undergoing major surgery. J Surg Res 2013 0.88
97 Acceptance and compliance with postpartum human papillomavirus vaccination. Obstet Gynecol 2012 0.88
98 Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy. J Genet Couns 2002 0.88
99 Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol 2004 0.87
100 Contemporary clinical management of endometrial cancer. Obstet Gynecol Int 2013 0.86
101 Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 2004 0.86
102 Morbidity and mortality of surgery for endometrial cancer in the oldest old. Am J Obstet Gynecol 2011 0.86
103 Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer 2014 0.86
104 The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Gynecol Oncol 2008 0.85
105 An economic analysis of robotically assisted hysterectomy. Obstet Gynecol 2014 0.85
106 Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2012 0.85
107 Assessing the adequacy of surgical staging for ovarian cancer. Gynecol Oncol 2006 0.84
108 Long-term semi-permanent catheter use for the palliation of malignant ascites. Gynecol Oncol 2006 0.84
109 What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? Gynecol Oncol 2010 0.84
110 Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. Am J Obstet Gynecol 2010 0.84
111 Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol 2005 0.84
112 Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol 2009 0.84
113 Recurrent vulvar carcinoma in pregnancy. Gynecol Oncol 2004 0.83
114 Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol 2007 0.83
115 Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy. Obstet Gynecol 2002 0.83
116 A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 2004 0.83
117 Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets 2013 0.82
118 Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006 0.82
119 Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol 2011 0.82
120 Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. Anticancer Res 2010 0.81
121 Stage IIIA endometrial carcinoma: outcome and predictors of survival. Obstet Gynecol 2009 0.81
122 Surgical and systemic management of endometrial cancer: an international survey. Arch Gynecol Obstet 2014 0.81
123 Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002 0.81
124 Risk and predictors of malignancy in women with endometrial polyps. Ann Surg Oncol 2011 0.81
125 Failure to rescue after major gynecologic surgery. Am J Obstet Gynecol 2013 0.81
126 Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. Am J Obstet Gynecol 2011 0.80
127 Patterns of care for locally advanced vulvar cancer. Am J Obstet Gynecol 2013 0.80
128 Current treatment strategies for endometrial cancer. Expert Rev Anticancer Ther 2008 0.80
129 What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Gynecol Oncol 2004 0.80
130 Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs 2015 0.80
131 Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol 2009 0.79
132 Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. Gynecol Oncol 2003 0.79
133 Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother 2009 0.79
134 CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 2006 0.79
135 Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer 2003 0.79
136 Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest 2013 0.79
137 Paclitaxel poliglumex for ovarian cancer. Expert Opin Investig Drugs 2011 0.78
138 Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 2007 0.78
139 Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration. J Oncol Pharm Pract 2009 0.77
140 Biologic therapies and personalized medicine in gynecologic malignancies. Obstet Gynecol Clin North Am 2012 0.77
141 The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax? Ann Surg Oncol 2012 0.77
142 Utilization and safety of sodium hyaluronate-carboxymethylcellulose adhesion barrier. Dis Colon Rectum 2013 0.77
143 Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol 2002 0.76
144 Human papillomavirus: emerging trends in detection and management. Curr Womens Health Rep 2002 0.76
145 Relationship of ovarian neoplasms and body mass index. J Reprod Med 2005 0.76
146 The role of Notch and gamma-secretase inhibition in an ovarian cancer model. Anticancer Res 2013 0.76
147 The new era of cervical cancer prevention: HPV vaccination. Gynecol Oncol 2008 0.76
148 Enhancing the needle count in the haystack: serial ultrasonography for low-to-moderate risk adnexal masses. Obstet Gynecol 2013 0.75
149 Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. Medscape J Med 2009 0.75
150 Fertility sparing therapy for ovarian cancer has inherent risks and benefits. Arch Gynecol Obstet 2005 0.75
151 Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report. J Reprod Med 2008 0.75
152 Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta. J Matern Fetal Neonatal Med 2013 0.75
153 Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Curr Pharm Des 2016 0.75
154 Detection and significance of parametrial micrometastases in early-stage cervical cancer. Anticancer Res 2011 0.75
155 Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor. Obstet Gynecol 2004 0.75
156 Access to conservative surgical therapy for adolescents with benign ovarian masses. Obstet Gynecol 2012 0.75
157 Unintended consequences: surgical complications in gynecologic cancer. Womens Health (Lond Engl) 2013 0.75
158 Safety of conservative management of ovarian masses during pregnancy. J Reprod Med 2013 0.75
159 Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. Gynecol Oncol 2004 0.75
160 Supporting gynecologic cancer research: the last 20 years and beyond. Gynecol Oncol 2011 0.75